Who are Viking Therapeutics, Inc.'s main suppliers?

Viking Therapeutics, Inc. (VKTX) key suppliers include: ONE-PACIFIC-HEIGHTS-LLC, Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, Alnylam Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc. and 22 more. View the full supplier network at chainsifter.com/chain/VKTX.

Who are Viking Therapeutics, Inc.'s major customers?

Viking Therapeutics, Inc. (VKTX) key customers include: iBio, Inc., Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, LGNZZ, LGNZZ and 9 more. View the full customer network at chainsifter.com/chain/VKTX.

What sector is Viking Therapeutics, Inc. in?

Viking Therapeutics, Inc. (VKTX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Viking Therapeutics, Inc. Supplier List (VKTX): 27 Verified Suppliers

27Suppliers

14Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Viking Therapeutics, Inc. (VKTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

44Total relationships

3Distinct source URLs

6High confidence

0.731Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Viking Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ONE-PACIFIC-HEIGHTS-LLC	ONE-PACIFIC-HEIGHTS-LLC	92%	In November 2021, the Company entered into an Office Lease (the “Office Lease”) with One Pacific Heights. LLC.
LGND	Ligand Pharmaceuticals Incorporated	90%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
LGND	Ligand Pharmaceuticals Incorporated	90%	Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapi…
ALNY	Alnylam Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
ALNY	Alnylam Pharmaceuticals, Inc.	72%	Reciprocal relationship from ALNY graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ALNY g…
ARWR	Arrowhead Pharmaceuticals, Inc.	72%	Reciprocal relationship from ARWR graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, suc…
ARWR	Arrowhead Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
BHC	Bausch Health Companies Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
BHC	Bausch Health Companies Inc.	72%	Reciprocal relationship from BHC graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from BHC graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from BHC grap…
CRBP	Corbus Pharmaceuticals Holdings, Inc.	72%	Reciprocal relationship from CRBP graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting …
GLMD	Galmed Pharmaceuticals Ltd.	72%	Reciprocal relationship from GLMD graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, suc…
GLMD	Galmed Pharmaceuticals Ltd.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
GPCR	Structure Therapeutics Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
GPCR	Structure Therapeutics Inc.	72%	Reciprocal relationship from GPCR graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, suc…
GYRE	Gyre Therapeutics, Inc.	72%	Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product can…
HEPA	Hepion Pharmaceuticals, Inc.	72%	Reciprocal relationship from HEPA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from HEPA graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, suc…
HEPA	Hepion Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. Ther…
LGNZZ	LGNZZ	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
LGNZZ	LGNZZ	72%	Reciprocal relationship from LGNZZ graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therap…
MDGL	Madrigal Pharmaceuticals, Inc.	72%	Reciprocal relationship from MDGL graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, suc…
MDGL	Madrigal Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
ORANY	ORANY	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therap…
SEPN	Septerna, Inc.	72%	Reciprocal relationship from SEPN graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from SEPN g…
TERN	Terns Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
TERN	Terns Pharmaceuticals, Inc.	72%	Reciprocal relationship from TERN graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from TERN graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, suc…

Viking Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Ver…
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND g…
LGND	Ligand Pharmaceuticals Incorporated	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
LGNZZ	LGNZZ	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
LGNZZ	LGNZZ	72%	Reciprocal relationship from LGNZZ graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therap…
MTVA	MetaVia Inc.	72%	Reciprocal relationship from MTVA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from MTVA g…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
ASCLETIS-BIOSCIENCE-CO-LTD-GANNEX-PHARMA-CO-LTD	ASCLETIS-BIOSCIENCE-CO-LTD-GANNEX-PHARMA-CO-LTD	62%	estitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significa…
ASCLETIS-PHARMACEUTICALS-CO-LTD-ASCLETIS-PHARMA-	ASCLETIS-PHARMACEUTICALS-CO-LTD-ASCLETIS-PHARMA-	62%	estitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significa…
CORDEN-PHARMA-COLORADO-INC	CORDEN-PHARMA-COLORADO-INC	62%	. As stock-based compensation expense recognized is based on options ultimately expected to vest, the fair value of each employee option grant during the three months ended March 31, 2026 was estimat…
HELSINN-GROUP	HELSINN-GROUP	62%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
IN-CATALYST-PHARMS-INC	IN-CATALYST-PHARMS-INC	62%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
ONE-PACIFIC-HEIGHTS-LLC	ONE-PACIFIC-HEIGHTS-LLC	62%	. As stock-based compensation expense recognized is based on options ultimately expected to vest, the fair value of each employee option grant during the three months ended March 31, 2026 was estimat…

Viking Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
VKTX-DEBT-13375	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2017-03-31.
VKTX-DEBT-13374	Warrants outstanding: 637087	90%	xbrl warrant detail from xbrl 2020-12-31.

Viking Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Viking Therapeutics, Inc..

Viking Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
VKTX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 418 tracked holders.

Viking Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
AGEN	Agenus Inc.	100.00	2
LONA	LeonaBio, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	1	['supplier']
ELUT	Elutia Inc.	100.00	2
HEPA	Hepion Pharmaceuticals, Inc.	100.00	1	['supplier']
BBIO	BridgeBio Pharma, Inc.	100.00	2
BHC	Bausch Health Companies Inc.	100.00	1	['supplier']
GYRE	Gyre Therapeutics, Inc.	100.00	1	['supplier']
CRMD	CorMedix Inc.	100.00	2
ARWR	Arrowhead Pharmaceuticals, Inc.	100.00	1	['supplier']
GPCR	Structure Therapeutics Inc.	100.00	2	['supplier']
GNMSF	Genmab A/S	100.00	2
IBIO	iBio, Inc.	100.00	1	['customer', 'supplier']
CLDX	Celldex Therapeutics, Inc.	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
LGNZZ	LIGAND PHARMACEUTICALS INC	100.00	1	['customer', 'supplier']
AZN	AstraZeneca PLC	100.00	2
NVO	Novo Nordisk A/S	100.00	2
JSPR	Jasper Therapeutics, Inc.	100.00	2

Viking Therapeutics, Inc. Supply Chain